1,2,3-Propanetricarboxylicacid, 2-hydroxy-, gallium salt (1:1)

Suppliers

Names

[ Name ]:
1,2,3-Propanetricarboxylicacid, 2-hydroxy-, gallium salt (1:1)

[Synonym ]:
GALLIUMCITRATEANDCOMPOUNDS
Citric acid,gallium salt (1:1)
gallium citrate
2-Hydroxy-1,2,3-propanetricarboxylic acid gallium salt

Chemical & Physical Properties

[ Boiling Point ]:
309.6ºC at 760mmHg

[ Molecular Formula ]:
C₆H₁₁GaO₇

[ Molecular Weight ]:
264.87000

[ Flash Point ]:
155.2ºC

[ Exact Mass ]:
263.97600

[ PSA ]:
132.13000

[ Vapour Pressure ]:
5.73E-05mmHg at 25°C

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GE7675000

CAS REGISTRY NUMBER :: 27905-02-8

LAST UPDATED :: 199106

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C6-H5-O7.Ga

MOLECULAR WEIGHT :: 258.83

WISWESSER LINE NOTATION :: QV1XQVQ1VQ &-GA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2227 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 37 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 55500 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 167 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 74 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - domestic

DOSE/DURATION :: 37 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - domestic

DOSE/DURATION :: 56 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

Related Compounds

3-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(2-(6-oxopyridazin-1(6H)-yl)ethyl)propanamide
2-(2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(6-(methylsulfonyl)benzo[d]thiazol-2-yl)acetamide
2-(2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-(3-(furan-2-yl)-6-oxopyridazin-1(6H)-yl)ethyl)acetamide
(4-Chloropyridin-2-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone
5-cyclopropyl-N-(5-(dimethylcarbamoyl)-4-methylthiazol-2-yl)isoxazole-3-carboxamide
N,N,4-trimethyl-2-(3-(4-oxoquinazolin-3(4H)-yl)propanamido)thiazole-5-carboxamide
(1r,3s,5R,7S)-methyl 3-(3-(1H-tetrazol-1-yl)benzamido)adamantane-1-carboxylate
methyl 3-[2-(1H-indol-1-yl)acetamido]adamantane-1-carboxylate
(1r,3s,5R,7S)-methyl 3-(2-oxo-1,2-dihydropyridine-3-carboxamido)adamantane-1-carboxylate
(1r,3s,5R,7S)-methyl 3-(1H-indole-2-carboxamido)adamantane-1-carboxylate

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.